Article
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.
Emerging infectious diseases - 1 Jul 2003
Lim Sue, Bast Darrin, McGeer Allison, de Azavedo Joyce, Low Donald E
Abstract excerpt
Clinical antimicrobial susceptibility breakpoints are used to predict the clinical outcome of antimicrobial treatment. In contrast, microbiologic breakpoints are used to identify isolates that may be categorized as susceptible when applying clinical breakpoints but harbor resistance mechanisms that result in their reduced susceptibility to the agent being tested. Currently, the National Committee for Clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.